NCT03718286View on ClinicalTrials.gov

Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

March 11, 2019

Primary Completion Date

June 30, 2021

Study Completion Date

October 8, 2021

Conditions
ST Elevation Myocardial InfarctionAcute Coronary SyndromeHypercholesterolemiaHyperlipidemiasDyslipidemiasPhysiological Effects of Drugs
Interventions
DRUG

Alirocumab

150 mg alirocumab administered prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.

OTHER

Sham Control

Sham injection prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.

Trial Locations (1)

L8L 2X2

Hamilton Health Sciences, General Hospital, Hamilton

Sponsors
All Listed Sponsors
lead

Population Health Research Institute

OTHER